Genistein potentiates wild-type and delta F508-CFTR channel activity.
Effects of genistein on wild-type (wt) and delta F508-cystic fibrosis transmembrane conductance regulator (CFTR) were studied in NIH/3T3 cells stably transfected with wt or mutant CFTR cDNA. As measured by I- efflux, half-maximal concentration of agonist (K1/2) for forskolin-dependent activation was greater for delta F508-CFTR than wt-CFTR. Genistein decreased the K1/2 for both forms of the channel and increased the maximal activity of delta F508-CFTR by 3.7-fold. In cell-attached patches, 10 microM forskolin induced minimal delta F508-CFTR activity with characteristic prolonged closed times (estimated time constant, > 30 s). Genistein increased the forskolin-induced macroscopic currents of wt-CFTR and delta F508-CFTR by 3- and 19-fold, respectively. Variance analysis suggested that in the presence of forskolin and genistein the open probabilities (Po) of wt- and delta F508-CFTR were identical. In single-channel studies, at maximal adenosine 3',5'-cyclic monophosphate (cAMP) stimulation, genistein increased the Po of wt-CFTR by prolonging the open time, but, at submaximal cAMP stimulation, the Po was increased by prolonging the open time and shortening the closed time. In excised patches with CFTR channels preactivated in the cell-attached mode, genistein increased ATP-dependent wt- and delta F508-CFTR current about twofold by prolonging the open time. Our results thus suggest that phosphorylation-dependent activation of delta F508-CFTR is defective and that genistein corrects this defect at least in part by binding to the CFTR protein.
Hwang
T C
TC
Department of Physiology, Dalton Cardiovascular Research Center, University of Missouri-Columbia 65211, USA.
Wang
F
F
Yang
I C
IC
Reenstra
W W
WW
D016475:3T3 Cells; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000096:biosynthesis / Q000187:drug effects / Q000502:physiology*; D018076:DNA, Complementary; D019833:Genistein; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D007454:Iodides / Q000378:metabolism; D007529:Isoflavones / Q000494:pharmacology*; D007700:Kinetics; D008564:Membrane Potentials / Q000502:physiology; D051379:Mice; D017354:Point Mutation; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000187:drug effects; D014162:Transfection
C505032:CFTR protein, human; D018076:DNA, Complementary; D006131:Growth Inhibitors; D007454:Iodides; D007529:Isoflavones; D011994:Recombinant Proteins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005576:Colforsin; D000255:Adenosine Triphosphate; D019833:Genistein